Clinical Trial Update: Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer

View source ↗

Summary

An ongoing clinical trial (NCT06820333) evaluates [18F] PSMA-1007 PET imaging for primary staging of prostate cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA-1007 (PSMA-1007 radiotracer)

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Prostate Cancer (Adenocarcinoma) | Status: RECRUITING